Akebia Therapeutics

Intangible assets: Vafseo holds five‑year NCE exclusivity to March 27, 2029 and a growing Orange Book patent estate with listed expirations reaching into 2034 to 2036, but the therapeutic class is not unique in the U.S. (GSK’s daprodustat is approved for dialysis patients). Brand equity is early stage.

Switching costs: once dialysis organizations adopt observed three‑times‑weekly protocols, operational familiarity supports persistence, yet payer rebasing and alternative oral/injectable options limit lock‑in. Network effects: none.

Cost advantage: oral dosing can save chair time and logistics compared to injections, but any unit cost edge is constrained by CMS rate‑setting. Efficient scale: dialysis distribution is consolidated and contract‑driven, which helps access but also compresses margins under rebasing.

Overall, multiple modest moats exist but are policy‑sensitive; durability is capped by reimbursement mechanics and class competition.